ALLR
$1.25
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs.
Recent News
Allarity closes $20M financing for stenoparib advancement
Allarity (ALLR) Therapeutics closed a $20 million non-convertible debt financing with Streeterville Capital. The transaction is structured as a note purchase agreement pursuant to which the Company issued two non-convertible promissory notes: a promissory note in the original principal amount of $10,930,000 and a secured promissory note in the original principal amount of $10,000,000, together providing approximately $20 million in net proceeds to the Company. The financing is expected to extend
Allarity CEO says 2026 represents an ‘inflection point’
Allarity (ALLR) Therapeutics issued a letter to shareholders from the Company’s CEO, which read, in part, “As we close out 2025, I write to you with both optimism and gratitude. Your continued support has helped steer Allarity Therapeutics through a period of meaningful transformation and disciplined execution. This December marks two years since I assumed the role of CEO. Since that time, our efforts have been anchored by a clear and focused strategy centered on advancing stenoparib, our novel
Sector Update: Health Care Stocks Higher Late Afternoon
Health care stocks advanced late Tuesday afternoon with the NYSE Health Care Index rising 0.6% and t
BC-Most Active Stocks
Raytech Holding Ltd. 21,549,901 3.68